Close Menu

fibrosis

The company said proceeds will be used for working capital, and may also be used to acquire or invest in complementary businesses or technologies.

Veracyte will offer 5 million shares at $10.25 per share. It has granted underwriters an option to purchase an additional 750,000 shares.

This Week in PNAS

In PNAS this week: computational approach for finding heterotic patterns in hybrid wheat, single-cell RNA-seq study of fetal brain development, and more.

Despite an initial focus on cardiovascular disease, Miragen has moved programs in hematological cancer and fibrosis to the front of its pipeline.

NEW YORK (GenomeWeb News) – Molecular imaging firm Edinburgh Molecular Imaging has received £4 million ($6.5 million) in a Series A investment, life science capital venture fund Epidarex Capital announced today.

Regulus Therapeutics remains on track to filing an investigational new drug application for its microRNA-targeting hepatitis C treatment RG-101 next year, with a second candidate — likely for fibrosis or cancer — to be added to the company's formal pipeline before the end of 2013

Roughly three years after partnering with Quark Pharmaceuticals to develop siRNA-based treatments for fibrotic diseases, Japan’s Nitto Denko has initiated its first clinical trial of an RNAi drug.

The management of Regulus Therapeutics last week provided a few new details on the company's pipeline, promising that it would have two microRNA drug candidates ready for clinical trials before the end of next year.

NEW YORK (GenomeWeb News) – KineMed today announced an agreement with GlaxoSmithKline for the use of KineMed's biomarker discovery platform in therapeutic areas of interest for the drug manufacturer.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Epistem today announced a research collaboration with GlaxoSmithKline to use its amplification technology to gain a better understanding of fibrosis.

Pages

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.